Baili Tianheng (688506.SH): GNC-077 monoclonal antibody injection for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notification.
Baili Tianheng (688506.SH) announced that the company has recently received approval from the National Medical Products Administration (NMPA)...
Baoli Tianheng (688506.SH) announced that the company recently received the official approval letter for the clinical trial of the company's independently developed innovative biopharmaceutical GNC-077 from the National Medical Products Administration (NMPA).
According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, the clinical trial application for GNC-077 multi-specific antibody injection, which was accepted on July 16, 2024, meets the relevant requirements for drug registration, and the company has been authorized to conduct clinical trials for late-stage solid tumors.
Related Articles
CITIC TELECOM (01883): Resumption of trading in the afternoon of September 18th as the franchise contract period is extended.
PROSPER CONS (06816): The construction of the Qingdao International Shipping Center will greatly benefit the cross-border trade business.
CITIC TELECOM (01883): Resuming trading in the afternoon of September 18 to extend the franchise agreement period.
CITIC TELECOM (01883): Resumption of trading in the afternoon of September 18th as the franchise contract period is extended.
PROSPER CONS (06816): The construction of the Qingdao International Shipping Center will greatly benefit the cross-border trade business.
CITIC TELECOM (01883): Resuming trading in the afternoon of September 18 to extend the franchise agreement period.
